流感嗜血桿菌血清群b型鑒定

廣州健侖生物科技有限公司

我司還有很多種血清學(xué)診斷血清、血液檢測(cè)、免疫檢測(cè)產(chǎn)品、毒素檢測(cè)、凝集檢測(cè)、酶免檢測(cè)、層析檢測(cè)、免疫熒光檢測(cè)產(chǎn)品，。

（ MOB：楊永漢）

【流感知識(shí)】

流感嗜血桿菌是一種沒(méi)有運(yùn)動(dòng)力的革蘭氏陰性桿菌。它是于1892年由費(fèi)佛博士在流行性感冒的瘟疫中發(fā)現(xiàn)。它一般都是好氧生物，但可以成長(zhǎng)為兼性厭氧生物。
流感嗜血桿菌zui初被誤認(rèn)為是流行性感冒的病因，但直至1933年，當(dāng)發(fā)現(xiàn)流行性感冒的病毒性病原后，才消除了這種誤解。不過(guò)，流感嗜血桿菌仍會(huì)導(dǎo)致其他不同種類的病癥。  

本試劑盒主要用于對(duì)病菌細(xì)菌進(jìn)行檢測(cè)，利用快速玻片凝集檢測(cè)技術(shù)

嗜血桿菌屬血清群A型鑒定

嗜血桿菌屬血清群A型鑒定

嗜血桿菌屬血清群A型鑒定

嗜血桿菌屬血清群A型鑒定

流感嗜血桿菌A/B型凝集抗血清Haemophilus

流感嗜血桿菌A/B型凝集抗血清Haemophilus

流感嗜血桿菌A/B/C型血清群

流感嗜血桿菌A/B/C型血清群

流感嗜血桿菌A/B/C3型凝集抗血清

流感嗜血桿菌A/B/C3型凝集抗血清

a型流感嗜血桿菌診斷血清

a型流感嗜血桿菌診斷血清

玻片凝集法鑒定流感嗜血桿菌

玻片凝集法鑒定流感嗜血桿菌

b型2ml流感嗜血桿菌快速玻片法檢測(cè)血清

b型2ml流感嗜血桿菌快速玻片法檢測(cè)血清

A型、B型流感嗜血桿菌多群血清

A型、B型流感嗜血桿菌多群血清

流感嗜血桿菌血清群b型鑒定

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】    楊永漢

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103

有證據(jù) 提示本病存在免疫調(diào)節(jié)異常。本病的含IgA1循環(huán)免疫復(fù)合物中， 發(fā)現(xiàn)有多聚的IgA1類風(fēng)濕因子；抗α重鏈Fab片斷的IgG抗體增多 而IgM抗體減少。有趣的是HIV感染者也存在類似的抗免疫球蛋白 模式，卻不發(fā)生腎臟IgA沉積。這證明單單這些循環(huán)的自身抗體存 在，并不是系膜IgA沉積的原因。此外目前還發(fā)現(xiàn)了二種抗內(nèi)皮細(xì) 胞的自身抗體（屬I(mǎi)gG）。本病腎組織中常有C3沉積，提示激活了 補(bǔ)體旁路途徑。然而IgA本身無(wú)激活補(bǔ)體的能力，IgA免疫復(fù)合物 雖可激活補(bǔ)體旁路途徑，但它結(jié)合補(bǔ)體和C3b的能力很弱。通常認(rèn) 為在腎臟發(fā)生補(bǔ)體激活和形成膜攻擊復(fù)合物，需有IgG-IgA復(fù)合物 ，但是本病腎組織中有IgA和C3沉積而沒(méi)有IgG或IgM沉積卻很常見(jiàn) 。因此，本病補(bǔ)體激活的機(jī)制尚不清楚。細(xì)胞免疫也參與了發(fā)病 機(jī)制。已發(fā)現(xiàn)本病可有T輔助細(xì)胞（CD4）增加和T抑制細(xì)胞（CD8 ）減少；具有轉(zhuǎn)換IgM合成為IgA合成的Ta4細(xì)胞增加，與之有關(guān)的 Sa1等位基因的頻度也增加；引起IgA同型轉(zhuǎn)換的TGFβ、促進(jìn)產(chǎn)生 IgA的B淋巴細(xì)胞分化的IL-5和介導(dǎo)IgA產(chǎn)生的IL-4形成均有增加 。雖然T細(xì)胞和B細(xì)胞均參與了增加IgA合成的過(guò)程，但I(xiàn)gA合成增 多并不是系膜區(qū)IgA沉積的原因，因?yàn)樵贗gA多發(fā)性骨髓瘤病人中 罕見(jiàn)有組織IgA沉積。因此，結(jié)構(gòu)-免疫學(xué)/理化異常才可能是系膜 IgA沉積的原因。
Evidence suggests that there is an immunoregulatory abnormality in this disease. Among the IgA1 circulating immune complexes of this disease, polyvalent IgA1 rheumatoid factor was found; the IgG antibody against the α heavy chain Fab fragment increased while the IgM antibody decreased. Interestingly, HIV-infected persons also have similar anti-immunoglobulin patterns but no renal IgA deposition. This proves that these circulating autoantibodies alone are not responsible for the deposition of mesangial IgA. In addition, two anti-endothelial autoantibodies (genus IgG) have been discovered. C3 deposition often occurs in the renal tissue of this disease, suggesting activation of the complement alternative pathway. However, IgA itself has no ability to activate complement. IgA immune complexes can activate the complement alternative pathway, but its ability to bind complement and C3b is weak. It is generally believed that IgG-IgA complexes are required for complement activation and membrane attack complexes in the kidney, but it is common for the disease to have IgA and C3 deposition but no IgG or IgM deposition. Therefore, the mechanism of complement activation in this disease is not yet clear. Cellular immunity also participates in the pathogenesis. It has been found that the disease may have increased T-helper (CD4) and T-suppressor (CD8) cells; the number of Ta4 cells synthesized by converting IgM synthesis to IgA increases, and the frequency of Sa1 alleles associated therewith also increases; causing IgA Isotype-transformed TGFβ, IL-5 that promotes IgA-producing B lymphocyte differentiation, and IL-4 formation that mediates IgA production are all increased. Although both T and B cells are involved in the process of increasing IgA synthesis, increased IgA synthesis is not responsible for IgA deposition in the mesangial area because of the rare tissue IgA deposition in IgA patients with multiple myeloma. Therefore, structural-immunological/physicochemical abnormalities may be responsible for the deposition of mesangial IgA.